Table III.
Enriched pathways in modules.
| Module | Gene set | FDR | Nodes |
|---|---|---|---|
| 1 | ECM-receptor interaction | 1.94×10−12 | GOLM1, MIA3, LAMA5, ITGA9, LAMB2, ITGB6, MGAT4A, QSOX1, ITGB4, MFGE8, COL6A1, GAS6, LAMA2, ADAM10 |
| Focal adhesion | 3.88×10−10 | ||
| PI3K-Akt signaling pathway | 9.34×10−09 | ||
| 2 | PPAR signaling pathway | 6.92×10−08 | ACLY, ACSL1, CPT2, ACOX1, ACACB, FASN, SCD |
| AMPK signaling pathway | 3.16×10−05 | ||
| Metabolic pathways | 6.41×10−05 | ||
| 3 | Pathways in cancer | 3.63×10−05 | GNB2, ADCY5, ANAPC5, BUB3, CASR, NDC80, PLK1, |
| Gap junction | 1.4×10−04 | VHL, RNF144B, AREL1, PTGER3, NDE1, GPSM1, TRIM36, | |
| Cell cycle | 1.5×10−04 | FBXW7, LPAR1, ADCY9, CKAP5, MKRN1, BDKRB2 |
FDR, false discovery rate; ECM, epithelial-mesenchymal transition; PPAR, peroxisome proliferator-activated receptor.